NAUT 2.95 Nautilus Biotechnology, Inc.
| Range: | 2.19-3.455 | Vol Avg: | 71334 | Last Div: | 0 | Changes: | 0.15 |
| Beta: | 1.03 | Cap: | 0.36B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Aug 07 2020 | Empoloyees: | 164 | ||
| CUSIP: | 63909J108 | CIK: | 0001808805 | ISIN: | US63909J1088 | Country: | US |
| CEO: | Mr. Sujal M. Patel | Website: | https://www.nautilus.bio | ||||
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow